Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US ... - GSK
Jul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin …
GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the …
Dec 11, 2023 · GSK plc (LSE/NYSE: GSK) today announced t he European Commission (EC) has granted marketing authorisation for Jemperli (dostarlimab) in combination with carboplatin …
US FDA expands Jemperli (dostarlimab) plus chemotherapy approval ... - GSK
Aug 1, 2024 · GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel …
Jemperli (dostarlimab) plus chemotherapy approved in the US as ... - GSK
Jul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and …
About JEMPERLI (dostarlimab-gxly) - GSK
Aug 17, 2021 · GlaxoSmithKline (GSK) plc today announced the US Food and Drug Administration (FDA) approved a new indication for JEMPERLI (dostarlimab-gxly), a …
GSK bags sought-after Jemperli okay in endometrial cancer
Jan 22, 2025 · The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy …
GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel …
Primary Advanced or Recurrent Endometrial Cancer Treatment
Discover JEMPERLI (dostarlimab-gxly) + CP, an IO-based treatment for primary advanced or recurrent endometrial cancer. See full Indication, Safety, & PI. Find more information about …
GSK's Jemperli prolongs life in endometrial cancer trial. Will FDA ...
Oct 30, 2023 · Adding Jemperli to chemotherapy significantly extended the life spans of patients with primary advanced or first recurrent endometrial cancer in the phase 3 RUBY trial, GSK …
GSK blows Jemperli marching horn against Keytruda with new …
Aug 1, 2024 · On Thursday, the FDA expanded the endometrial cancer use for GSK’s Jemperli, used in combination with chemotherapy, to include patients with mismatch repair proficient …